St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, is participating in Heart Rhythm 2014, the Heart Rhythm Society’s Annual Scientific Sessions. Clinical evidence about the company’s cardiac rhythm management and ablation technologies will be provided in 38 sessions, including three late-breaking clinical trial sessions. The company’s latest technologies will be on display May 7-10 in booth 1002 at the Moscone Convention Center in San Francisco.
“St. Jude Medical’s long-standing commitment to answering some of the medical community’s most challenging clinical questions about heart rhythm disorders and heart failure is reflected in a notable podium presence at the 2014 HRS Scientific Sessions,” said Dr. Mark D. Carlson, chief medical officer for St. Jude Medical. “We will continue investing in important research and developing technologies that reduce costs and improve patient outcomes.”
Key sessions in which new data regarding St. Jude Medical technologies will be presented include:
Late-Breaking Clinical Trial SessionsHeart failure and abnormal heart rhythms are expensive epidemic diseases, and St. Jude Medical is relentless in its quest to find novel treatments that benefit patients. Three important technologies from the company will be highlighted in this year’s Late Breaking Clinical Trial Sessions:
- Increased Adherence to Remote Monitoring is Associated with Reduced Mortality in Both Pacemaker and Defibrillator Patients: New findings on the Merlin™ Remote Monitoring System will be presented on May 8 at 2:30 p.m. PT in Room 305, Moscone South
- Dual-targeted Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS HEART): First-in man Experience: Early findings will be presented on May 8 at 2:45 p.m. PT in Room 305, Moscone South. Products being evaluated are exclusively for clinical investigations and not being used in accordance with their approved indications for use.
- Chronic Performance of Leadless Cardiac Pacing: One Year Follow-up to the LEADLESS Trial: Chronic data about the Nanostim™ leadless pacemaker from the CE Mark study will be presented on May 9 at 8 a.m. PT in Room 305, Moscone South. The Nanostim leadless pacemaker is being evaluated under a U.S. Food and Drug Administration (FDA) Investigational Device Exception (IDE).
- Reduced Mortality with Quadripolar Versus Bipolar Left Ventricular Leads in Cardiac Resynchronization Therapy: Poster from Dr. Mintu Turakhia et al will be on display during the Featured Poster Session on May 7 at 6 p.m. in the Exhibit Hall
- Reduced Costs Post CRT with Quadripolar LV leads compared to Bipolar LV leads: Poster from Dr. Raffaele Corbisiero et al will be on display during the Featured Poster Session on May 7 at 6 p.m. PT in the Exhibit Hall
- Multipoint Left Ventricular Pacing in Cardiac Resynchronization Therapy Patients Provides Similar Acute Hemodynamic Improvement Regardless of QRS Duration or Lead Location: Poster from Dr. Carlo Pappone et al will be on display on May 8 at 9:30 a.m. PT in the Exhibit Hall. The Quadra Assura MP™ CRT-D is being evaluated under a U.S. FDA IDE.
- Hospitalization Rates and Associated Cost Analysis of Quadripolar versus Bipolar CRT-D: a comparative analysis of a single-center prospective Italian registry: Will be presented by Dr. Giovanni Forleo on May 9 at 1:45 p.m. PT in room 2010, Moscone West